<DOC>
	<DOCNO>NCT02182011</DOCNO>
	<brief_summary>Primary objective : evaluate procoagulant effect TNK-tPA compare rt-PA streptokinase , administer patient AMI , measure concentration TAT 2 hour start treatment versus baseline value . Secondary objective : change baseline concentration TAT 6 24 hour ; change baseline concentration D-dimers , F1+2 , PAI-1 , PAP 2 , 6 24 hour . Incidence adverse event ( AE 's ) , -hospital complication , major minor bleeding serious adverse event .</brief_summary>
	<brief_title>A Study Investigate Procoagulant Effect Tenecteplase ( TNK-tPA ) , Alteplase ( Rt-PA ) Streptokinase ( SK ) Administered Patients With Acute Myocardial Infarction ( AMI )</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<mesh_term>Tenecteplase</mesh_term>
	<mesh_term>Streptokinase</mesh_term>
	<criteria>Onset symptom AMI within 6 hour randomisation A twelvelead electrocardiogram ( ECG ) show STsegment elevation ≥ 0.1 millivolt ( mV ) two limb lead , ≥ 0.2 mV two contiguous precordial lead indicative AMI , new leave bundlebranch block Age ≥ 18 Hypertension define blood pressure &gt; 180/110 mmHg ( systolic BP &gt; 180 mmHg and/or diastolic BP &gt; 110 mmHg ) repeat measurement current admission prior randomisation Use abciximab ( ReoPro® ) within precede 7 day eptifibatide ( Integrilin® ) tirofiban ( aggrastat® ) within past 48 hour Use heparin within precede 12 hour Current therapeutic oral anticoagulation Major surgery , biopsy parenchymal organ , significant trauma within 2 month Any minor head trauma trauma occur onset current myocardial infarction Any known history stroke transient ischemic attack dementia Any known structural damage central nervous system Ruptured aortic aneurism Active bleeding Prolonged cardiopulmonary resuscitation ( &gt; 10 minute ) previous two week Pregnancy lactation , parturition within previous 30 day . Women childbearing potential must negative pregnancy test Any known active participation another investigative drug study device protocol past 30 day Previous enrolment study Any condition investigator feel would place patient increase risk investigational therapy initiate Inability follow protocol comply followup requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>